journal
MENU ▼
Read by QxMD icon Read
search

Biomarkers in Cancer

journal
https://www.readbyqxmd.com/read/29977116/circulating-micrornas-as-biomarkers-in-diffuse-large-b-cell-lymphoma-a-pilot-prospective-longitudinal-clinical-study
#1
Céline Bouvy, Adeline Wannez, Fabienne George, Carlos Graux, Christian Chatelain, Jean-Michel Dogné
Objectives: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a need to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation, and an overview of the resistance to chemotherapeutics. The aim of this study was to evaluate the use of microRNAs found in plasma from patients with DLBCL as biomarkers of tumor evolution in these patients...
2018: Biomarkers in Cancer
https://www.readbyqxmd.com/read/29872358/clean-colorectum-at-diagnostic-colonoscopy-subsequent-detection-of-extracolonic-malignancies-by-plasma-protein-biomarkers
#2
Michael Wilhelmsen, Ib J Christensen, Lars N Jørgensen, Mogens R Madsen, Jesper Vilandt, Thore Hillig, Michael Klærke, Knud T Nielsen, Søren Laurberg, Susan Gawel, Xiaoping Yang, Gerard Davis, Anne Meike Heijboer, Frans Martens, Hans J Nielsen
Introduction: Most of the subjects undergoing diagnostic colonoscopy do not have neoplastic bowel lesions. Potentially, some of the symptoms may therefore be caused by extracolonic malignancy, and subjects with persisting symptoms may need subsequent examinations. Blood-based, cancer-associated biomarkers may aid in directing the examinations for other specific malignant diseases. Methods: EDTA plasma samples available from a previous prospective study of subjects undergoing diagnostic colonoscopy were used for analysis of 18 protein biomarkers...
2018: Biomarkers in Cancer
https://www.readbyqxmd.com/read/29497340/data-mining-of-small-rna-seq-suggests-an-association-between-prostate-cancer-and-altered-abundance-of-5-transfer-rna-halves-in-seminal-fluid-and-prostatic-tissues
#3
Joseph M Dhahbi, Hani Atamna, Luke A Selth
Extracellular RNAs are gaining clinical interest as biofluid-based noninvasive markers for diseases, especially cancer. In particular, derivatives of transfer RNA (tRNA) are emerging as a new class of small-noncoding RNAs with high biomarker potential. We and others previously reported alterations in serum levels of specific tRNA halves in disease states including cancer. Here, we explored seminal fluid for tRNA halves as potential markers of prostate cancer. We found that 5' tRNA halves are abundant in seminal fluid and are elevated in prostate cancer relative to noncancer patients...
2018: Biomarkers in Cancer
https://www.readbyqxmd.com/read/29467585/integrating-circulating-immunological-and-sputum-biomarkers-for-the-early-detection-of-lung-cancer
#4
Jian Su, Qixin Leng, Yanli Lin, Jie Ma, Fangran Jiang, Cheng-Ju Lee, HongBin Fang, Feng Jiang
We have demonstrated that assessments of microRNA (miRNA) expressions in circulating peripheral blood mononucleated cell (PBMC) and sputum specimens, respectively, may help diagnose lung cancer. To assess the individual and combined analysis of the miRNAs across the different body fluids for lung cancer early detection, we analyse a panel of 3 sputum miRNAs (miRs-21, 31, and 210) and a panel of 2 PBMC miRNAs (miRs-19b-3p and 29b-3p) in a discovery cohort of 68 patients with lung cancer and 66 cancer-free smokers...
2018: Biomarkers in Cancer
https://www.readbyqxmd.com/read/29343995/humanmethylation450k-array-identified-biomarkers-predict-tumour-recurrence-progression-at-initial-diagnosis-of-high-risk-non-muscle-invasive-bladder-cancer
#5
Mark O Kitchen, Richard T Bryan, Richard D Emes, Christopher J Luscombe, K K Cheng, Maurice P Zeegers, Nicholas D James, Lyndon M Gommersall, Anthony A Fryer
Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment...
2018: Biomarkers in Cancer
https://www.readbyqxmd.com/read/29147078/long-noncoding-rnas-as-a-key-player-in-hepatocellular-carcinoma
#6
REVIEW
Mrigaya Mehra, Ranjit Chauhan
Hepatocellular carcinoma (HCC) is a major malignancy in the liver and has emerged as one of the main cancers in the world with a high mortality rate. However, the molecular mechanisms of HCC are still poorly understood. Long noncoding RNAs (lncRNAs) have recently come to the forefront as functional non-protein-coding RNAs that are involved in a variety of cellular processes ranging from maintaining the structural integrity of chromosomes to gene expression regulation in a spatiotemporal manner. Many recent studies have reported the involvement of lncRNAs in HCC which has led to a better understanding of the underlying molecular mechanisms operating in HCC...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/29085239/more-accurate-oral-cancer-screening-with-fewer-salivary-biomarkers
#7
James Michael Menke, Md Shahidul Ahsan, Suan Phaik Khoo
Signal detection and Bayesian inferential tools were applied to salivary biomarkers to improve screening accuracy and efficiency in detecting oral squamous cell carcinoma (OSCC). Potential cancer biomarkers are identified by significant differences in assay concentrations, receiver operating characteristic areas under the curve (AUCs), sensitivity, and specificity. However, the end goal is to report to individual patients their risk of having disease given positive or negative test results. Likelihood ratios (LRs) and Bayes factors (BFs) estimate evidential support and compile biomarker information to optimize screening accuracy...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28874886/in-search-for-optimal-targets-for-intraoperative-fluorescence-imaging-of-peritoneal-metastasis-from-colorectal-cancer
#8
Charlotte Es Hoogstins, Benjamin Weixler, Leonora Sf Boogerd, Diederik J Hoppener, Hendrica Ajm Prevoo, Cornelis Fm Sier, Jacobus Wa Burger, Cornelis Verhoef, Shadvhi Bhairosingh, Arantza Farina Sarasqueta, Jacobus Burggraaf, Alexander L Vahrmeijer
Peritoneal metastasis (PM) occurs in about 10% of patients with colorectal cancer (CRC). Fluorescence imaging can enhance contrast between cancerous and benign tissue, enabling the surgeon to clearly visualize PM during cytoreductive surgery. This study assessed the suitability of different biomarkers as potential targets for tumor-targeted imaging of PM of CRC. Tissue samples from primary tumor and PM from patients with CRC were obtained from the pathology archives and immunohistochemical stainings were performed...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28607544/analysis-of-fascin-1-in-relation-to-gleason-risk-classification-and-nuclear-ets-related-gene-status-of-human-prostate-carcinomas-an-immunohistochemical-study-of-clinically-annotated-tumours-from-the-wales-cancer-bank
#9
Matthew T Jefferies, Christopher S Pope, Howard G Kynaston, Alan R Clarke, Richard M Martin, Josephine C Adams
Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28579847/correlation-between-preoperative-serum-carcinoembryonic-antigen-levels-and-expression-on-pancreatic-and-rectal-cancer-tissue
#10
L S F Boogerd, F A Vuijk, C E S Hoogstins, H J M Handgraaf, M J M van der Valk, P J K Kuppen, C F M Sier, C J H van de Velde, J Burggraaf, A Fariña-Sarasqueta, Alexander L Vahrmeijer
Carcinoembryonic antigen (CEA)-targeted imaging and therapeutic agents are being tested in clinical trials. If CEA overexpression in malignant tissue corresponds with elevated serum CEA, serum CEA could assist in selecting patients who may benefit from CEA-targeted agents. This study aims to assess the relationship between serum CEA and CEA expression in pancreatic (n = 20) and rectal cancer tissues (n = 35) using histopathology. According to local laboratory standards, a serum CEA >3 ng/mL was considered elevated...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28469485/biomarkers-for-hepatocellular-carcinoma
#11
REVIEW
Jiatao Lou, LingFei Zhang, Shaogang Lv, Chenzi Zhang, Shuai Jiang
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28469484/preoperative-serum-carcinoembryonic-antigen-as-a-marker-for-predicting-the-outcome-of-three-cancers
#12
Jingzhu Nan, Juan Li, Xiujuan Li, Guanghong Guo, Xinyu Wen, Yaping Tian
BACKGROUND: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. OBJECTIVE: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. METHODS: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28096697/mir-486-3p-mir-139-5p-and-mir-21-as-biomarkers-for-the-detection-of-oral-tongue-squamous-cell-carcinoma
#13
Zujian Chen, Tianwei Yu, Robert J Cabay, Yi Jin, Ishrat Mahjabeen, Xianghong Luan, Lei Huang, Yang Dai, Xiaofeng Zhou
Oral tongue squamous cell carcinoma (TSCC) is a complex disease with extensive genetic and epigenetic defects, including microRNA deregulation. The aims of the present study were to test the feasibility of performing the microRNA profiling analysis on archived TSCC specimens and to assess the potential diagnostic utility of the identified microRNA biomarkers for the detection of TSCC. TaqMan array-based microRNA profiling analysis was performed on 10 archived TSCC samples and their matching normal tissues. A panel of 12 differentially expressed microRNAs was identified...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27721658/selecting-targets-for-tumor-imaging-an-overview-of-cancer-associated-membrane-proteins
#14
REVIEW
Martin C Boonstra, Susanna W L de Geus, Hendrica A J M Prevoo, Lukas J A C Hawinkels, Cornelis J H van de Velde, Peter J K Kuppen, Alexander L Vahrmeijer, Cornelis F M Sier
Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In addition to therapeutic targeting, some of these compounds can also be applied for tumor visualization before or during surgery, after conjugation with radionuclides and/or near-infrared fluorescent dyes. The majority of these tumor-targeting compounds are directed against cell membrane-bound proteins...
2016: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27721657/association-of-mthfr-c677t-gene-polymorphism-with-breast-cancer-in-north-india
#15
Mohammad Waseem, Syed Rizwan Hussain, Shashank Kumar, Mohammad Serajuddin, Farzana Mahdi, Satyendra Kumar Sonkar, Cherry Bansal, Mohammad Kaleem Ahmad
BACKGROUND: Breast cancer is one of the most common malignancies in women and is associated with a variety of risk factors. The functional single-nucleotide polymorphism (SNP) C677T in the gene encoding 5,10-methylenetetrahydrofolate reductase ( MTHFR ) may lead to decreased enzyme activity and affect the chemosensitivity of tumor cells. This study was designed to investigate the association of MTHFR gene polymorphism (SNP) in the pathogenesis of breast cancer among the North Indian women population...
2016: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27679534/pet-metabolic-biomarkers-for-cancer
#16
REVIEW
Etienne Croteau, Jennifer M Renaud, Marie Anne Richard, Terrence D Ruddy, François Bénard, Robert A deKemp
The body's main fuel sources are fats, carbohydrates (glucose), proteins, and ketone bodies. It is well known that an important hallmark of cancer cells is the overconsumption of glucose. Positron emission tomography (PET) imaging using the glucose analog (18)F-fluorodeoxyglucose ((18)F-FDG) has been a powerful cancer diagnostic tool for many decades. Apart from surgery, chemotherapy and radiotherapy represent the two main domains for cancer therapy, targeting tumor proliferation, cell division, and DNA replication-all processes that require a large amount of energy...
2016: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27486347/oncogenes-the-passport-for-viral-oncolysis-through-pkr-inhibition
#17
REVIEW
Janaina Fernandes
The transforming properties of oncogenes are derived from gain-of-function mutations, shifting cell signaling from highly regulated homeostatic to an uncontrolled oncogenic state, with the contribution of the inactivating mutations in tumor suppressor genes P53 and RB, leading to tumor resistance to conventional and target-directed therapy. On the other hand, this scenario fulfills two requirements for oncolytic virus infection in tumor cells: inactivation of tumor suppressors and presence of oncoproteins, also the requirements to engage malignancy...
2016: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27398030/quantitative-perfusion-and-permeability-biomarkers-in-brain-cancer-from-tomographic-ct-and-mr-images
#18
REVIEW
Armin Eilaghi, Timothy Yeung, Christopher d'Esterre, Glenn Bauman, Slav Yartsev, Jay Easaw, Enrico Fainardi, Ting-Yim Lee, Richard Frayne
Dynamic contrast-enhanced perfusion and permeability imaging, using computed tomography and magnetic resonance systems, are important techniques for assessing the vascular supply and hemodynamics of healthy brain parenchyma and tumors. These techniques can measure blood flow, blood volume, and blood-brain barrier permeability surface area product and, thus, may provide information complementary to clinical and pathological assessments. These have been used as biomarkers to enhance the treatment planning process, to optimize treatment decision-making, and to enable monitoring of the treatment noninvasively...
2016: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27398029/tissue-and-serum-associated-biomarkers-of-hepatocellular-carcinoma
#19
REVIEW
Ranjit Chauhan, Nivedita Lahiri
Hepatocellular carcinoma (HCC), one of the leading causes of cancer deaths in the world, is offering a challenge to human beings, with the current modes of treatment being a palliative approach. Lack of proper curative or preventive treatment methods encouraged extensive research around the world with an aim to detect a vaccine or therapeutic target biomolecule that could lead to development of a drug or vaccine against HCC. Biomarkers or biological disease markers have emerged as a potential tool as drug/vaccine targets, as they can accurately diagnose, predict, and even prevent the diseases...
2016: Biomarkers in Cancer
https://www.readbyqxmd.com/read/27279751/predicting-clinical-outcomes-using-molecular-biomarkers
#20
REVIEW
Harry B Burke
Over the past 20 years, there has been an exponential increase in the number of biomarkers. At the last count, there were 768,259 papers indexed in PubMed.gov directly related to biomarkers. Although many of these papers claim to report clinically useful molecular biomarkers, embarrassingly few are currently in clinical use. It is suggested that a failure to properly understand, clinically assess, and utilize molecular biomarkers has prevented their widespread adoption in treatment, in comparative benefit analyses, and their integration into individualized patient outcome predictions for clinical decision-making and therapy...
2016: Biomarkers in Cancer
journal
journal
47141
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"